WO2004047839A8 - High concentration formulations of opioids and opioid derivatives - Google Patents

High concentration formulations of opioids and opioid derivatives

Info

Publication number
WO2004047839A8
WO2004047839A8 PCT/US2003/038174 US0338174W WO2004047839A8 WO 2004047839 A8 WO2004047839 A8 WO 2004047839A8 US 0338174 W US0338174 W US 0338174W WO 2004047839 A8 WO2004047839 A8 WO 2004047839A8
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
fentanyl
opioid
opioids
high concentration
Prior art date
Application number
PCT/US2003/038174
Other languages
French (fr)
Other versions
WO2004047839A1 (en
Inventor
Tai Wah Chan
Original Assignee
Durect Corp
Tai Wah Chan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp, Tai Wah Chan filed Critical Durect Corp
Priority to CA002507356A priority Critical patent/CA2507356A1/en
Priority to JP2004555827A priority patent/JP4510637B2/en
Priority to AU2003297608A priority patent/AU2003297608A1/en
Priority to CN2003801085558A priority patent/CN1735413B/en
Priority to EP03812057A priority patent/EP1585519A4/en
Publication of WO2004047839A1 publication Critical patent/WO2004047839A1/en
Publication of WO2004047839A8 publication Critical patent/WO2004047839A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides opioid formulations suitable for long-term delivery to a subject. The formulation of the invention comprises an opioid or opioid derivative (e.g., morphine, hydromorphone, fentanyl or a fentanyl congener), and an aqueous solvent comprising a low molecular weight carboxylic acid (e.g., C2-4, C2-7). The invention thus provides for formulations comprising morphine, hydromorphone, fentanyl or fentanyl congeners in concentrations significantly in excess of conventional aqueous formulations, e.g., on the order about 2-fold to about 10,000-fold greater than conventional formulations, e.g., currently commercially available formulations.
PCT/US2003/038174 2002-11-25 2003-11-25 High concentration formulations of opioids and opioid derivatives WO2004047839A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002507356A CA2507356A1 (en) 2002-11-25 2003-11-25 High concentration formulations of opioids and opioid derivatives
JP2004555827A JP4510637B2 (en) 2002-11-25 2003-11-25 High concentration formulations of opioids and opioid derivatives
AU2003297608A AU2003297608A1 (en) 2002-11-25 2003-11-25 High concentration formulations of opioids and opioid derivatives
CN2003801085558A CN1735413B (en) 2002-11-25 2003-11-25 High concentration formulations of opioids and opioid derivatives
EP03812057A EP1585519A4 (en) 2002-11-25 2003-11-25 High concentration formulations of opioids and opioid derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/305,252 US20040102476A1 (en) 2002-11-25 2002-11-25 High concentration formulations of opioids and opioid derivatives
US10/305,252 2002-11-25

Publications (2)

Publication Number Publication Date
WO2004047839A1 WO2004047839A1 (en) 2004-06-10
WO2004047839A8 true WO2004047839A8 (en) 2004-08-19

Family

ID=32325387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038174 WO2004047839A1 (en) 2002-11-25 2003-11-25 High concentration formulations of opioids and opioid derivatives

Country Status (7)

Country Link
US (2) US20040102476A1 (en)
EP (1) EP1585519A4 (en)
JP (2) JP4510637B2 (en)
CN (1) CN1735413B (en)
AU (1) AU2003297608A1 (en)
CA (1) CA2507356A1 (en)
WO (1) WO2004047839A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074803B2 (en) 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
CA2417727C (en) 2000-07-31 2009-09-01 Nycomed Danmark A/S Fentanyl composition for nasal administration
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
ES2360102T3 (en) 2003-03-26 2011-05-31 Egalet A/S SYSTEM FOR CONTROLLED RELEASE OF MORPHINE.
EP2168579B1 (en) * 2007-05-21 2017-10-11 Toray Industries, Inc. Oral preparation comprising specific organic acid, and method for improvement in dissolution property and chemical stability of oral preparation
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
MX361779B (en) * 2012-03-07 2018-12-17 Piramal Critical Care Ltd Improved stability of hydromorphone hydrochloride solutions.
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
JP6370802B2 (en) * 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド Long-acting buprenorphine transdermal delivery composition and methods of use thereof
EP3143988A1 (en) 2013-03-14 2017-03-22 Fresenius Kabi Deutschland GmbH Injectable morphine formulations
AU2014230836C1 (en) 2013-03-14 2018-12-20 Fresenius Kabi Deutschland Gmbh Packaging system for oxygen-sensitive drugs
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB584497A (en) * 1944-04-17 1947-01-16 Winifred Mercer Pitkin Therapeutic preparations for intramuscular and subcutaneous injection and methods of making the same
US3285922A (en) * 1962-01-26 1966-11-15 Research Corp N-cyclopropylmethyl-and -cyclobutyl-methyl-morphinans
US3141823A (en) * 1962-09-04 1964-07-21 Res Lab Dr C Janssen N V Method for producing analgesia
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) * 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US3998834A (en) * 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4167574A (en) * 1978-03-13 1979-09-11 Janssen Pharmaceutica, N.V. N-phenyl-N-(4-piperidinyl)amides
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) * 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
IT1160131B (en) * 1983-12-12 1987-03-04 Rotta Research Lab PROGLUMIDE COMPOSITIONS AND PHARMACEUTICAL PREPARATIONS THAT INCLUDE IT FOR USE IN HUMAN PAIN THERAPY
US4681560A (en) * 1984-03-16 1987-07-21 Pudenz-Schulte Medical Research Corp. Subcutaneous infusion reservoir and pump system
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4725852A (en) * 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US5487739A (en) * 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
NL9000634A (en) * 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting WATER-BASED SUSPENSION INJECTION PREPARATION, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THIS PREPARATION FOR PAIN RELIEF.
US5672167A (en) * 1990-05-21 1997-09-30 Recordati Corporation Controlled release osmotic pump
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
CA2038597A1 (en) * 1991-03-19 1992-09-20 Jose P. Garzaran A method and a pharmaceutical preparation for treating pain
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
WO1993010758A1 (en) * 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5489689A (en) * 1993-09-30 1996-02-06 Mallinckrodt Chemical, Inc. Preparation of piperidine derivatives
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
DE4415331A1 (en) * 1994-05-02 1995-11-09 Sobrevin Thread storage device with adjustable thread draw resistance
CA2189351C (en) * 1994-05-13 2008-12-30 Stephen J. Farr Narcotic containing aerosol formulation
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
JPH10513471A (en) * 1995-02-10 1998-12-22 メドトロニック、インコーポレイテッド Methods and devices for the administration of analgesics
US5729396A (en) * 1995-05-12 1998-03-17 Cirrus Logic, Inc. Fault tolerant sync mark detector enabled relative to a frequency of an acquisition preamble for sampled amplitude recording
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
RU2189221C2 (en) * 1996-02-02 2002-09-20 Элзэ Копэрейшн Method and device for administering active substance and method for treating prostate carcinoma patients
JPH09208465A (en) * 1996-02-07 1997-08-12 Takeda Chem Ind Ltd Morphine liquid for high-concentration injection
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
WO1997033566A2 (en) * 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
US5839497A (en) * 1996-03-19 1998-11-24 U-Mold Co., Ltd. Vertical die-casting method and apparatus
GB9605867D0 (en) * 1996-03-20 1996-05-22 Svedman Paul Transdermal device
US5861248A (en) * 1996-03-29 1999-01-19 Urocor, Inc. Biomarkers for detection of prostate cancer
US5798114A (en) * 1996-04-30 1998-08-25 Medtronic Incorporated Refillable body powered drug delivery techniques
TW411277B (en) * 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
WO1997049402A1 (en) * 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. Sustained release sufentanil compositions
US5722936A (en) * 1996-07-30 1998-03-03 Trulio; Bruce S. Veterinary avian oral speculum and method of use
US6203813B1 (en) * 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6126628A (en) * 1997-04-22 2000-10-03 Johnson & Johnson Professional, Inc. Fluid flow limiting device
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
SE9900961D0 (en) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
AU6046900A (en) * 1999-06-16 2001-01-02 Nastech Pharmaceutical Company, Inc Method for increasing the solubility of morphine and pharmaceutical compositionsprepared therefrom
ES2197792B1 (en) * 1999-06-16 2005-05-01 Nastech Pharmaceutical Co., Inc. PHARMACEUTICAL FORMULATIONS CONTAINING INTRANASAL MORPHINE.
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6436091B1 (en) * 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
KR20020009845A (en) * 2000-07-27 2002-02-02 이영길 Specific drug containing cataplasma and its composites
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives

Also Published As

Publication number Publication date
JP2010159270A (en) 2010-07-22
WO2004047839A1 (en) 2004-06-10
CA2507356A1 (en) 2004-06-10
EP1585519A1 (en) 2005-10-19
US20040102476A1 (en) 2004-05-27
EP1585519A4 (en) 2009-09-23
CN1735413A (en) 2006-02-15
JP4510637B2 (en) 2010-07-28
CN1735413B (en) 2010-05-12
US20110136847A1 (en) 2011-06-09
JP2006509772A (en) 2006-03-23
AU2003297608A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
WO2004047839A8 (en) High concentration formulations of opioids and opioid derivatives
AU2006271870B2 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
AU2003246627A1 (en) Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof
WO2003105767A3 (en) Antifungal parenteral products
WO2005009356A3 (en) Method for the preparation of controlled release formulations
WO2007041156A3 (en) Antibiotic formulations, unit doses, kits, and methods
ATE409461T1 (en) HFC SOLUTION FORMULATIONS CONTAINING AN ANTICHOLINERGIC
AP1760A (en) Platinum derivative pharmaceutical formulations.
GR3033869T3 (en) IMIDAZO 4,5-c]QUINOLINE AMINES
WO2005025500A3 (en) Process for preparing water soluble diterpenes and their applications
WO2004026256A3 (en) Sustained-release opioid formulations and methods of use
CA2359813A1 (en) Nicotine mucosal spray
GB0012850D0 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
WO2003099338A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2008061190A3 (en) Solvent extracted corn
MXPA04000028A (en) Pharmaceutical formulation for the intramuscular administration of fulvestrant.
WO2005007129A3 (en) Topical formulations with bioactive components
CA2427583A1 (en) Inhalable formulation of a solution containing a tiotropium salt
EP1219296A4 (en) Sebum production inhibitors
WO2004058303A3 (en) Compositions of benzoquinolizine carboxylic acid antibiotic drugs
WO2001068140A3 (en) Opioid formulations
HUP0301378A2 (en) Pharmaceutical composition containing a tiotropium salt in inhalative solution formulation
AU2003283055A1 (en) Opioid-receptor antagonists in transdermal systems having buprenorphine
EA200200415A1 (en) COMPOSITION OF PHARMACEUTICAL MEDIA
WO2003077885A3 (en) Free-base formulations of local anesthetics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 24/2004 UNDER (71) ADD "(FOR ALL DESIGNATED STATES BUT US)"; REPLACE UNDER (72) "CHAN, TAI, WAH" BY UNDER (71, 72) "CHAN, TAI, WAH"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004555827

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 168776

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2507356

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003812057

Country of ref document: EP

Ref document number: 1412/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20038A85558

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003812057

Country of ref document: EP